Scancell Holdings

#FDA #Investigational New Drug (IND) #Melanoma #Scancell Holdings

FDA clears IND application for melanoma treatment 

The US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a registration Phase III trial of iSCIB1+ Immunobody in advanced melanoma.  The application, submitted by biotechnology company Scancell Holdings, has been cleared with progression free survival as the agreed surrogate endpoint.  Scancell has completed the 140-patient SCOPE Phase II, open-label, multi-centre… Read More

#News #Regulatory

#Cancer research #Cancer vaccines #Collaboration #Immunology / Virology & Vaccines #NHS Cancer Vaccine Launch Pad #Scancell Holdings

In Conversation With: Phil L’Huillier, Scancell

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Phil L’Huillier, CEO of… Read More

#Cancer Research #News

Scan to diagnose head and neck cancer
#Cancer vaccine #Head and neck cancer #Oncology #Phase II trial #Scancell Holdings

Vaccine achieves early clinical validation in head and neck cancer

The combination of Scancell’s Modi-1 and a checkpoint blockade has shown promise in HPV negative head and neck squamous cell carcinoma (SCCHN) in an ongoing Phase IIa study.  The Phase IIa dose expansion ModiFY study is evaluating the safety, tolerability, and preliminary efficacy of Modi-1 in combination… Read More

#Cancer Research #News

#Cobra Biologics #Covid-19 #Scancell Holdings #Vaccines

Cobra Biologics to manufacture plasmids for Phase I clinical trial COVID-19 vaccine

Cobra Biologics is to manufacture Scancell Holdings COVID-19 vaccine. The agreement covers Good Manufacturing Practice (GMP) production of plasmid DNA needed to generate the DNA vaccine, against SARS-CoV-2, for use in a Phase I clinical trial in 2021 (COVIDITY). The project is funded by an Innovate UK grant awarded to… Read More

#Covid-19 #News